Biological DMARDs and disease modification in axial spondyloarthritis

Funding Information: Competing interests AS: Consulting/speaking fees from MSD, UCB, Novartis. SR: Research grant from MSD; Consultancy/speaking fees from AbbVie, Eli Lilly, MSD, Novartis, UCB, Sanofi. DvdH: Consulting fees AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Celg...

ver descrição completa

Detalhes bibliográficos
Autor principal: Sepriano, Alexandre (author)
Outros Autores: Ramiro, Sofia (author), Van Der Heijde, Desirée (author), Landewé, Robert (author)
Formato: review
Idioma:eng
Publicado em: 2021
Assuntos:
ankylosing
biological therapy
epidemiology
spondylitis
Immunology and Allergy
Rheumatology
Immunology
Texto completo:http://hdl.handle.net/10362/124277
País:Portugal
Oai:oai:run.unl.pt:10362/124277

Texto Completo

http://hdl.handle.net/10362/124277

Registros relacionados